TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
暂无分享,去创建一个
G. Mufti | N. Lea | B. Czepulkowski | R. Ireland | A. Mohamedali | Alexander Smith | S. Mian | Sabine Pomplun | Ghulam J Mufti | Robin Ireland | Alexander E Smith | Austin G Kulasekararaj | Syed A Mian | Azim M Mohamedali | Pramila Krishnamurthy | Nicholas C Lea | Joop Gäken | Coralie Pennaneach | Barbara Czepulkowski | Judith C Marsh | A. Kulasekararaj | J. Marsh | S. Pomplun | J. Gäken | P. Krishnamurthy | C. Pennaneach | Joop Gäken
[1] W. McGuire,et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.
[2] B. Ebert,et al. The genetic basis of myelodysplastic syndromes. , 2010, Hematology/oncology clinics of North America.
[3] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[4] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[5] D. Christiansen,et al. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Mufti,et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. , 2010, Blood.
[7] M. Guiguet,et al. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. , 1997, British Journal of Cancer.
[8] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[9] S. Chevret,et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.
[10] R. Hills,et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis , 2009, Leukemia.
[11] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Quesnel,et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.
[13] Dekan der Mathematisch-Naturwissenschaftlichen,et al. Functional characterization of , 2014 .
[14] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[15] K. Sirotkin,et al. The NCBI dbGaP database of genotypes and phenotypes , 2007, Nature Genetics.
[16] R. Berger,et al. Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.
[17] E. Wattel,et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. , 1995, Leukemia.
[18] A. Tefferi,et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.
[19] M. McDevitt,et al. TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p , 2009, Leukemia.
[20] H. Kaneko,et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.
[21] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[22] L. Feuk,et al. Detection of large-scale variation in the human genome , 2004, Nature Genetics.
[23] I. Campbell,et al. Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. , 1996, British Journal of Cancer.
[24] G. Mufti,et al. Functional characterization of CD4+ T cells in aplastic anemia. , 2012, Blood.
[25] A. Schulz,et al. P53 mutations in myelodysplastic syndromes. , 1992, Leukemia.
[26] R. Wilson,et al. Next-generation sequencing of cancer genomes: back to the future. , 2009, Personalized medicine.
[27] M. Taniwaki,et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.
[28] E. Hurt,et al. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator , 2006, Cancer biology & therapy.
[29] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[30] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[31] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[32] John C Reed,et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[34] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[35] J. Kutok,et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. , 2011, Blood.
[36] Li Ding,et al. Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.